Witnessing the stock’s movement on the chart, on Wednesday, Lilly(Eli) & Co (NYSE: LLY) set off with pace as it heaved 1.75% to $826.57, before settling in for the price of $812.35 at the close. Taking a more long-term approach, LLY posted a 52-week range of $623.78-$935.62.
The Healthcare sector firm’s twelve-monthly sales growth has been 18.77% for the last half of the decade. Meanwhile, its Annual Earning per share during the time was 18.77%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 74.57%. This publicly-traded company’s shares outstanding now amounts to $946.83 million, simultaneously with a float of $849.83 million. The organization now has a market capitalization sitting at $782.31 billion.
Lilly(Eli) & Co (LLY) Ownership Facts and Figures
Nothing is more important than checking the behaviour of major investors towards the stock of the Drug Manufacturers – General industry. Lilly(Eli) & Co’s current insider ownership accounts for 10.21%, in contrast to 73.38% institutional ownership. According to the most recent insider trade that took place on Oct 10 ’25, this organization’s 10% Owner sold 3,658 shares at the rate of 863.24, making the entire transaction reach 3,157,722 in total value, affecting insider ownership by 94,533,320. Preceding that transaction, on Oct 09 ’25, Company’s 10% Owner sold 10,602 for 852.49, making the whole transaction’s value amount to 9,038,055. This particular insider is now the holder of 94,536,978 in total.
Lilly(Eli) & Co (LLY) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of 6.92 per share during the current fiscal year.
Lilly(Eli) & Co’s EPS increase for this current 12-month fiscal period is 74.57% and is forecasted to reach 30.20 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 41.43% through the next 5 years, which can be compared against the 18.77% growth it accomplished over the previous five years trading on the market.
Lilly(Eli) & Co (NYSE: LLY) Trading Performance Indicators
Let’s observe the current performance indicators for Lilly(Eli) & Co (LLY). It’s Quick Ratio in the last reported quarter now stands at 1.00. Alongside those numbers, its PE Ratio stands at $54.81, and its Beta score is 0.41. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 14.69. Similarly, its price to free cash flow for trailing twelve months is now 160.15.
In the same vein, LLY’s Diluted EPS (Earnings per Share) trailing twelve months is recorded 15.08, a figure that is expected to reach 6.19 in the next quarter, and analysts are predicting that it will be 30.20 at the market close of one year from today.
